Abstract 278P
Background
Radiotherapy is an effective treatment option for local control of prostate cancer, but its role in the treatment of oligometastatic prostate cancer (omPCa) remains unclear. This study aimed to investigate the potential survival benefit of full-coverage radiotherapy in patients with omPCa.
Methods
A retrospective analysis was conducted on patients with omPCa who received full-coverage radiotherapy between July 2012 and June 2022. Full-coverage radiotherapy was defined as radiotherapy to all lesions, including the primary site and metastatic lesions. Overall survival (OS) was the primary endpoint, and biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) were the secondary endpoint. The Kaplan-Meier method was used to estimate univariate analysis, and the log-rank test was used to conduct multivariate analysis.
Results
A total of 33 patients, including 31 de novo oligometastatic hormone-sensitive prostate cancer (omHSPC) patients and 2 oligometastatic castration-resistant prostate cancer (omCRPC) patients, were enrolled in the study. The median follow-up was 38.8 months (range: 4.2–70.6 months). The survival rates at 2, 3, and 5 years were 100%, 95.7%, and 81.2%, respectively. The median bPFS was 58.9 months (95% CI: 47.7 - 70.1 months). The median rPFS is 55.3 months (95% CI: 39.9 -70.8 months). According to the univariate analysis, TURP prior to radiotherapy, presence of symptoms related to the lesions, and the pre-radiotherapy status of CRPC were associated with poorer survival. Multivariate analysis showed EBRT synchronized with ADT or chemotherapy (p=0.016), non-CRPC status before radiotherapy(p=0.000), and PSA levels more than 1 ng/ml before radiotherapy ( p=0.014) may be associated with longer rPFS. Both univariate and multivariate studies have demonstrated that the coexistence of lymph node and bone metastases is associated with a higher risk of biochemical recurrence (p=0.02). The occurrence of acute adverse reactions of Grade 3 or higher was not observed.
Conclusions
Full-coverage radiotherapy with an optimistic bPFS and rPFS may improve the OS of patients with oligometastatic prostate cancer. Further prospective studies are warranted to confirm the findings of this retrospective analysis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Radiation Oncology, Shanghai Changhai Hospital, the Naval Medical Universit.
Funding
The First Affiliated Hospital of Navy Medical University “234 Subject Climbing Program” (2019YPT004), the First Affiliated Hospital of Naval Medical University “Youth Development Program”(2021JCQNO3).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract